Table 3 Changes in glycemic parameters from baseline to week 76
SAXA 2.5 mg q.A.M. (n = 74) | SAXA 5 mg q.A.M. (n = 74) | SAXA 2.5/5 mg q.A.M. (n = 71) | SAXA 5 mg q.P.M. (n = 72) | Control (n = 74) | |
|---|---|---|---|---|---|
HbA 1c (%) (repeated measures analysis) | |||||
BL, n | 67 | 69 | 69 | 70 | 68 |
n with observed data at 76 weeks | 24 | 34 | 28 | 26 | 31 |
BL, mean (SE) | 8.0 (0.11) | 7.9 (0.11) | 8.0 (0.13) | 7.9 (0.11) | 7.8 (0.11) |
Adj mean change from BL, mean (SE) | −0.84 (0.122) | −0.41 (0.108) | −0.60 (0.118) | −0.34 (0.117) | −0.29 (0.114) |
95% CI | (−1.07, –0.60) | (−0.63, –0.20) | (−0.83, –0.37) | (−0.57, –0.12) | (−0.52, –0.07) |
FPG (mg/dL) (repeated measures analysis)* | |||||
BL, n | 70 | 71 | 71 | 71 | 72 |
n with observed data at 76 weeks | 20 | 28 | 22 | 23 | 26 |
BL, mean (SE) | 157 (4.0) | 162 (4.2) | 171 (6.2) | 160 (5.3) | 160 (5.5) |
Adj mean change from BL, mean (SE) | −12 (5.0) | −1 (4.4) | −15 (4.9) | 1 (4.8) | 0.1 (4.6) |
95% CI | (−21.8, –2.1) | (−10.1, 7.3) | (−24.0, –4.9) | (−8.4, 10.3) | (−9.0, 9.1) |
HbA 1c <7.0% (LOCF) | |||||
N | 67 | 69 | 69 | 70 | 68 |
n (%) | 27 (40.3) | 22 (31.9) | 30 (43.5) | 22 (31.4) | 23 (33.8) |
95% CI | (28.5, 53.0) | (21.2, 44.2) | (31.6, 56.0) | (20.9, 43.6) | (22.8, 46.3) |
PPG–AUC (mg·min/dL) (repeated measures analysis)* | |||||
BL, n | 44 | 43 | 41 | 39 | 41 |
n with observed data at 76 weeks | 30 | 35 | 27 | 29 | 33 |
BL, mean (SE) | 47053 (1529.8) | 49512 (1621.9) | 48084 (1673.4) | 44498 (1813.4) | 46111 (1938.3) |
Adj mean change from BL, mean (SE) | −5859 (1498.3) | −4163 (1429.2) | −8511 (1571.7) | −4700 (1547.4) | −3788 (1465.6) |
95% CI | (−8821, –2897) | (−6988, –1338) | (−11618, –5404) | (−7759, –1642) | (−6685, –891) |